# (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy

> **NCT00354341** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 170 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Epoetin beta

## Key facts

- **NCT ID:** NCT00354341
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2016-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354341, "(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00354341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*